Table 1. Socio-demographic, behavioral and clinical characteristics of the HIV-infected women.
| Characteristic (N) | Neg/CIN1 (%) | CIN2+ (%) | Total (%) |
| Age (years) (N = 364) | |||
| <35 | 172 (50.3) | 15 (68.2) | 187 (51.3) |
| ≥35 | 170 (49.7) | 7 (31.8) | 177 (48.7) |
| Race/ethnicity (N = 363) | |||
| White | 153 (44.9) | 10 (45.5) | 163 (44.9) |
| Non-white | 188 (55.1) | 12 (54.5) | 200 (55.1) |
| Years of formal education (N = 363) | |||
| <5 | 81 (23.8) | 3 (13.6) | 84 (23.1) |
| 5–8 | 117 (34.3) | 8 (36.4) | 125 (34.5) |
| >8 | 14 3(41.9) | 11 (50.0) | 154 (42.4) |
| Married/living with partner (N = 364) | |||
| Yes | 152 (44.4) | 6 (27.3) | 158 (43.4) |
| No | 190 (55.6) | 16 (72.7) | 206 (56.6) |
| Age at first sexual intercourse (years) (N = 300) | |||
| ≤16 | 140 (41.4) | 12(54.5) | 185 (51.4) |
| >16 | 198 (58.6) | 10 (45.5) | 175 (48.6) |
| Current sexual partners (N = 364) | |||
| Yes | 202 (59.1) | 15 (68.2) | 217 (59.6) |
| No | 140 (40.9) | 7 (31.8) | 147 (40.4) |
| Number of lifetime sexual partners (N = 361) | |||
| 0–1 | 35 (10.3) | 3 (13.6) | 38 (10.5) |
| 2–3 | 96 (28.3) | 2 (9.1) | 98 (27.2) |
| 4 or more | 208 (61.4) | 17 (77.3) | 225 (62.3) |
| Tobacco use (N = 363) | |||
| Yes, current tobacco use | 65(19.1) | 9 (40.9) | 74 (20.4) |
| Yes, previous tobacco use | 85 (24.9) | 2 (9.1) | 87 (24.0) |
| No | 191 (56.0) | 11 (50.0) | 202 (55.6) |
| Number of pregnancies (N = 363) | |||
| None | 28 (8.2) | 3 (8.5) | 31 (8.5) |
| One | 80 (23.5) | 2 (9.1) | 82 (22.6) |
| ≥2 | 233 (68.3) | 17(77.3) | 250 (68.9) |
| Number of vaginal deliveries (N = 359) | |||
| None | 143 (42.4) | 7 (31.8) | 150 (41.8) |
| One | 84 (24.9) | 8(36.4) | 92 (25.6) |
| ≥ 2 | 110 (32.6) | 7 (31.8) | 117 (32.6) |
| Use of contraceptive hormones (oral/injectable) (N = 364) | |||
| Yes | 26 (7.6) | 1 (4.5) | 27 (7.4) |
| No | 316 (92.4) | 21 (95.5) | 337 (92.6) |
| Nadir CD4+ T-cell count (cells/mm3) (N = 342) | |||
| <350 | 196 (60.9) | 17 (85.0) | 213 (62.3) |
| ≥350 | 126 (39.1) | 3 (15.0) | 129 (37.7) |
| Baseline CD4+ T-cell count (cells/mm3) (N = 303) | |||
| <350 | 141 (49.8) | 13 (65.0) | 154 (50.8) |
| ≥350 | 142 (50.2) | 7 (35.0) | 149 (49.2) |
| AIDS defining illness (N = 366) | |||
| Yes | 66 (19.2) | 8 (36.4) | 74 (20.2) |
| No | 278 (80.8) | 14 (63.6) | 292 (79.8) |
| HAART for more than 60 days at cohort entry (N = 340) | |||
| Yes | 80 (25.2) | 10 (45.5) | 90 (26.5) |
| No | 238 (74.8) | 12 (54.5) | 250 (73.5) |
| Time since last Pap test (N = 357) | |||
| ≤1 year | 173 (51.6) | 12 (54.5) | 185 (51.8) |
| 1–3 years | 108 (32.2) | 8 (36.2) | 116 (32.5) |
| >3 years | 54(16.1) | 2 (9.1) | 56 (15.7) |
| Self-reported history of HPV (N = 351) | |||
| Yes | 57 (17.3) | 6 (27.3) | 63 (17.9) |
| No/does not know | 272 (82.7) | 16 (72.7) | 288 (82.1) |
| VIN and/or VAIN (N = 322) | |||
| Yes | 17 (5.6) | 5 (23.8) | 22 (6.8) |
| No | 284 (94.4) | 16 (76.2) | 300 (93.2) |
Percentages are given within the valid responses of each variable.
HAART: highly-active antiretroviral therapy, VIN: vulvar intraepithelial neoplasia, VAIN: vaginal intraepithelial neoplasia.